NASDAQ:SPRO

Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?

Retrieved on: 
Thursday, March 14, 2024
Multimedia

Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.

Key Points: 
  • Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
  • Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
  • InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
  • We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Spero Therapeutics Inc. (NASDAQ: SPRO)

Retrieved on: 
Tuesday, November 21, 2023
Telephone

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of Spero Therapeutics Inc. (NASDAQ: SPRO) concerning possible breaches of fiduciary duty.

Key Points: 
  • NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of Spero Therapeutics Inc. (NASDAQ: SPRO) concerning possible breaches of fiduciary duty.
  • To obtain additional information, go to:
    or contact Joseph E. Levi, Esq.
  • either via email at [email protected] or by telephone at (212) 363-7500.
  • Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C.

SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, November 3, 2023
Class Action Lawsuit, Professional Services, Legal, FDA, Food, Rare, Treatment, Tebipenem, Telephone, Workforce, News, Infection, HBR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Urinary tract infection, P.C, Complicated, Jeanne Eagels, New Drug Application, NDA, Patient, Cryptocurrency, Pharmaceutical industry, Spero, Pyelonephritis

Our investigation concerns whether the board of directors of Spero have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Spero have breached their fiduciary duties to the company.
  • Spero, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States.
  • The Company's product candidates include Tebipenem Pivoxil Hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults.
  • On March 31, 2022, Spero issued a press release announcing the Company’s fourth quarter and full year 2021 financial results.

Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

Retrieved on: 
Tuesday, September 12, 2023
GSK, Tuck School of Business, PTC Therapeutics, Therapy, Lehman Brothers, Rice University, Syneos Health, Biotechnology, PTC, Business, Human Genome Sciences, Dartmouth College, History, CNS, Inotek Pharmaceuticals, Acquisition, Nature, Drug discovery, HGSI, Economics, Pharmaceutical industry, Sensorium

BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors.

Key Points: 
  • BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors.
  • “We are excited to welcome David to our Board,” said Dick Simon, Chief Executive Officer of Sensorium.
  • “He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages.
  • in economics and managerial studies from Rice University and an M.B.A. from the Tuck School of Business at Dartmouth College.

Spero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

Retrieved on: 
Monday, July 25, 2022
NASDAQ, Lists of schools in England, GLOBE, Tebipenem, Review, Workforce, NDA, FDA, Company, Pharmaceutical industry, Spero

LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) investors that a class action filed on behalf of investors. Spero investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) investors that a class action filed on behalf of investors.
  • Spero investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

DEADLINE ALERT for SPRO, LMPX, MF, and YQ: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, July 25, 2022
Time, IPO, Investment, GLOBE, Tebipenem, Registration statement, Twitter, Law, Workforce, NDA, Income, Education, NASDAQ, Mission statement, FDA, Company, Defendant, YQ, Lists of schools in England, Complaint, Suite, Mail, Public relations

LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, July 25, 2022 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

Bronstein, Gewirtz & Grossman, LLC Reminds Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action Deadline and Last Few Hours to Actively Participate

Retrieved on: 
Monday, July 25, 2022
Legal, Professional Services, Tebipenem, Court, Person, Workforce, NDA, NASDAQ, Review, FDA, Lists of schools in England, Complaint, LLC, Security (finance), Spero

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.

Key Points: 
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
  • The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Companys business, operations, and prospects.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Friday, July 22, 2022
Class Action Lawsuit, Professional Services, Legal, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Time, Tebipenem, Court, Food, Twitter, Law, Workforce, NDA, HBR, Therapy, New Drug Application, NASDAQ, Urinary tract infection, News, Review, FDA, Company, Defendant, Lists of schools in England, Suite, Pharmaceutical industry, Spero

On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.

Key Points: 
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • If you purchased or otherwise acquired Spero securities during the Class Period, you may move the Court no later than July 25, 2022 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Spero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

Retrieved on: 
Thursday, July 21, 2022
NASDAQ, Lists of schools in England, GLOBE, Tebipenem, Review, Workforce, NDA, FDA, Company, Pharmaceutical industry, Spero

LOS ANGELES, July 21, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) investors that a class action filed on behalf of investors. Spero investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.        Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

Key Points: 
  • LOS ANGELES, July 21, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) investors that a class action filed on behalf of investors.
  • Spero investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

SPRO FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors With Losses Over $100K to Secure Counsel Before Important July 25 Deadline in Securities Class Action – SPRO

Retrieved on: 
Thursday, July 21, 2022
Titan, Urinary tract infection, GLOBE, Tebipenem, Court, Food and Drug Administration, Twitter, Food, Class, New Drug Application, Workforce, NDA, WHY, Advertising, NASDAQ, THE, Facebook, I-Space (Chinese company), FDA, LinkedIn, Pyelonephritis, Lists of schools in England, Spero, TO, Medical device, Insurance, Tobacco

WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than July 25, 2022.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.